QIAGEN Partners with World’s Largest Sequencing Provider

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it has expanded its relationship with BGI, the world’s largest genomics organization, to provide QIAGEN’s Ingenuity^® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.

Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis‘ secure, cloud-based environment and gain access to its leading comprehensive gene variant data and genomic interpretation applications. BGI will provide Ingenuity Variant Analysis to customers in China, Hong Kong and Taiwan, with plans to expand to other regions throughout the year. BGI collaborates with more than 10,000 organizations and 30,000 partners worldwide, providing sequencing services for thousands of research projects, including large-scale genome initiatives.

“We are very pleased to expand QIAGEN’s relationship with BGI, the global leader in sequencing services. Integrating Ingenuity Variant Analysis into BGI’s highly reliable sequencing services will enable clients to accelerate workflows. They’ll be able to transform large quantities of genomic data into valuable molecular insights for research or clinical applications,” said Laura Furmanski, Head of QIAGEN’s Bioinformatics Business Area. “Bioinformatics solutions from QIAGEN are growing rapidly as scientists and healthcare professionals increasingly use genomic information to guide research and provide precise diagnosis for medical decision-making. We are committed to working with leading organizations such as BGI to make these improvements in life possible.”

Yingrui Li, Chief Scientist of BGI, said: “We welcome this opportunity to expand our relationship with QIAGEN for the benefit of BGI collaborators around the world. Coupling BGI’s world-class sequencing with the deep bioinformatics of Ingenuity Variant Analysis will give researchers an enhanced, integrated way to seamlessly move quickly from raw data to valuable insights.”

QIAGEN’s footprint in bioinformatics continues to expand with a product portfolio that includes the Ingenuity, CLC bio and BIOBASE product lines for analysis, interpretation and reporting of biological data from next-generation sequencing (NGS). The industry-leading Ingenuity Variant Analysis software quickly filters genetic variants in a secure, cloud-based environment to identify variants most likely to cause disease, drawing upon the Ingenuity Knowledge Base, a repository of expertly curated biological interactions and functional annotations created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases To learn more, please visit www.ingenuity.com. In March 2015, QIAGEN announced a reseller agreement with GATC Biotech, a leading European provider of DNA and RNA sequencing worldwide, to provide access to Ingenuity Variant Analysis as part of GATC’s sequencing services.